The Journal of Headache and Pain

Table 1 mTOQ-4 total score at baseline and week 4 by baseline acute treatment optimization subgroup

From: Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study

		Eptinezumab 100 mg	Placebo
Optimization subgroup	Time point	Mean (SD) [n]	Mean (SD) [n]
Very poor	Baseline	11.2 (2.4) [25]	11.6 (2.2) [25]
	Week 4	16.2 (5.3) [25]	13.9 (5.5) [24]
	Change from baseline	4.9 (4.9) [25]	2.4 (5.1) [24]
Poor	Baseline	17.0 (2.6) [138]	16.8 (2.7) [117]
	Week 4	19.6 (4.1) [130]	18.4 (3.3) [114]
	Change from baseline	2.5 (4.2) [130]	1.5 (3.0) [114]
Moderate	Baseline	21.5 (1.2) [46]	21.9 (1.0) [65]
	Week 4	22.1 (2.1) [44]	22.2 (2.0) [63]
	Change from baseline	0.6 (2.0) [44]	0.3 (1.8) [63]
Maximal	Baseline	23.8 (0.5) [28]	23.8 (0.5) [35]
	Week 4	23.1 (1.8) [26]	23.2 (2.0) [30]
	Change from baseline	-0.7 (1.9) [26]	-0.7 (2.0) [30]
Simplified subgroups
Poorly optimized	Baseline	16.1 (3.3) [163]	15.9 (3.3) [142]
	Week 4	19.0 (4.5) [155]	17.6 (4.1) [138]
	Change from baseline	2.9 (4.4) [155]	1.7 (3.5) [138]
Optimized	Baseline	22.4 (1.5) [75]	22.6 (1.2) [100]
	Week 4	22.5 (2.0) [71]	22.6 (2.0) [93]
	Change from baseline	0.1 (2.1) [71]	0.0 (1.9) [93]

Patients were grouped by baseline mTOQ-4 total scores into the following optimization categories: very poor (0), poor (1–5), moderate (6–7), and maximal (8). Simplified subgroups consist of patients with mTOQ-4 total scores in very poor (0) and poor (1–5) categories together, along with patients with total scores in the moderate (6–7) and maximal (8) categories grouped together. Epti, eptinezumab (100 mg); mTOQ-4/mTOQ-6, 4-item/6-item Migraine Treatment Optimization Questionnaire

Back to article page

ISSN: 1129-2377

Contact us

Submission enquiries: journalsubmissions@springernature.com